Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsIntegrated Home Care Services Step Therapy Policy …
    Ask Trek AI about this page
    CurrentIntegrated Home Care ServicesPolicy N/A

    Step Therapy Criteria for Select Pharmacy Drugs (AUVELITY and others)

    Customize your policy alerts

    Sign up for all integrated_home_care_services policy alerts

    Know when integrated_home_care_services releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines step therapy and automatic approval requirements for specified drugs for Integrated Home Care Services members; impacts prescribers and pharmacy prior authorization processes.

    Policy Summary
    PayerIntegrated Home Care Services
    PolicyStep Therapy Criteria for Select Pharmacy Drugs (AUVELITY and others)
    Policy CodePolicy N/A
    Change TypeRoutine review — no material changes
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionDocument prior trial or inability to use the listed generic therapies (e.g., SSRIs, SNRIs, bupropion, mirtazapine) to support automatic approval for Auvelity or Trintellix.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    16drug entries with step therapy criteria listed
    08/01/2026policy effective date
    1-800-457-4708phone for most recent drug list

    Coverage Criteria — Step Therapy and Prior Treatment Rules

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Anticoagulant prior therapy or age exception

    Apixaban (Eliquis/Eliquis Sprinkle) and Rivaroxaban (Xarelto): Covered when ONE of the following is met

    Oral anticoagulant prerequisite: Member has had previous treatment, contraindication, or intolerance with the reference tablet product (Eliquis/apixaban or Xarelto/rivaroxaban) OR the member is 17 years of age or younger.age <= 17 qualifies

    automatic approval when met

    Fenofibrate prior therapy requirement

    Fenofibrate micronized: Covered when BOTH of the following are met

    Fenofibrate prior products: Member had previous treatment with one strength of generic fenofibrate tablet (145 mg, 160 mg, 48 mg, or 54 mg) AND one strength of generic fenofibrate micronized capsule (200 mg, 134 mg, or 67 mg).N/A

    automatic approval when both met

    Fluvastatin prior therapy requirement

    Fluvastatin: Covered when ALL of the following are met

    Fluvastatin prerequisite: Member had previous treatment with ezetimibe AND one of the following statins: lovastatin, atorvastatin, rosuvastatin, simvastatin, or pravastatin.N/A

    automatic approval when met

    Seizure medication prior therapy requirement

    Levetiracetam-containing products (including Spritam): Covered when ALL of the following are met

    Levetiracetam prerequisite: Member had prior therapy with levetiracetam AND one of the following: lamotrigine, carbamazepine, topiramate, divalproex, or phenytoin.N/A

    automatic approval when met

    Ophthalmic prior therapy requirement

    Rhopressa and Rocklatan: Covered when ONE of the following is met

    Prostaglandin analog prerequisite: Member has had previous treatment, contraindication, or intolerance to a prostaglandin analog.N/A

    automatic approval when met

    Tramadol prior therapy requirement

    Tramadol: Covered when ONE of the following is met

    Tramadol prerequisite: Member has had previous treatment with immediate-release tramadol 50 mg tablet.N/A

    automatic approval when met

    Zypitamag prior therapy requirement

    Zypitamag: Covered when ONE of the following is met

    Zypitamag prerequisite: Member has had previous treatment with one of the following statins: simvastatin, pravastatin, lovastatin, atorvastatin, or rosuvastatin.N/A

    automatic approval when met

    For Auvelity, the policy notes an explicit exception: the step therapy prerequisite is not required for members with agitation associated with dementia due to Alzheimer’s disease. This exception means prescribers do not need to document trials or inability to use the listed generic antidepressant options for those members when requesting Auvelity.

    Provider Actions, Documentation & Automatic Approval Conditions

    Prior Authorization

    Auvelity prior therapy requirement

    Automatic approval is granted when the member has tried or cannot use a generic SSRI (citalopram, fluoxetine, paroxetine, or sertraline), a generic SNRI (venlafaxine or duloxetine), a generic bupropion product (75mg/100mg IR; 100mg/150mg/200mg SR; or 150mg/300mg XL), or mirtazapine. For Auvelity requests this criterion is not required for members with agitation associated with dementia due to Alzheimer's disease.

    • Document trial or documented inability to use one of the listed generic SSRIs, SNRIs, bupropion formulations, or mirtazapine for automatic approval.
    Prior Authorization

    Trintellix prior therapy requirement

    Automatic approval is granted when the member has tried or cannot use a generic SSRI (citalopram, fluoxetine, paroxetine, or sertraline), a generic SNRI (venlafaxine or duloxetine), a generic bupropion product (75mg/100mg IR; 100mg/150mg/200mg SR; or 150mg/300mg XL), or mirtazapine. The same prior-therapy exception that applies to Auvelity (see Auvelity criteria) is noted.

    • Document trial or documented inability to use one of the listed generic SSRIs, SNRIs, bupropion formulations, or mirtazapine for automatic approval.
    Prior Authorization

    Oral anticoagulant prior therapy or age-based approval

    Automatic approval for apixaban (Eliquis/Eliquis Sprinkle) or rivaroxaban (Xarelto) is given when the member has had previous treatment, a contraindication, or intolerance with the reference tablet product, or when the member is 17 years of age or younger.

    • For Eliquis/Eliquis Sprinkle: prior treatment, contraindication, or intolerance with Eliquis (apixaban) tablets OR age ≤ 17.
    • For Xarelto/rivaroxaban: prior treatment with Xarelto/rivaroxaban tablets OR age ≤ 17.
    Prior Authorization

    Prostaglandin analog prior therapy

    Automatic approval for Rhopressa or Rocklatan requires prior treatment with, or a documented contraindication or intolerance to, a prostaglandin analog.

    • Document prior therapy with a prostaglandin analog or documentation of contraindication/intolerance for automatic approval.
    Prior Authorization

    Fluvastatin prior statin + ezetimibe requirement

    Automatic approval for fluvastatin is granted when the member has had previous treatment with ezetimibe and one of the listed statins (lovastatin, atorvastatin, rosuvastatin, simvastatin, or pravastatin).

    • Document prior treatment with ezetimibe and one listed statin to meet the requirement for automatic approval.
    Prior Authorization

    Zypitamag prior statin requirement

    Automatic approval for Zypitamag is granted when the member has had previous treatment with one of the following statins: simvastatin, pravastatin, lovastatin, atorvastatin, or rosuvastatin.

    • Document prior treatment with one of the listed statins for automatic approval.
    Prior Authorization

    Tramadol prior IR tramadol requirement

    Automatic approval for tramadol is granted when the member has had previous treatment with immediate‑release tramadol 50 mg tablet.

    • Document prior treatment with IR tramadol 50 mg tablet for automatic approval.
    Step Therapy

    Auvelity step requirement

    Prior to approval, require a trial or documentation that the member cannot use a generic SSRI (citalopram, fluoxetine, paroxetine, or sertraline), a generic SNRI (venlafaxine or duloxetine), a generic bupropion product (75mg/100mg IR; 100mg/150mg/200mg SR; or 150mg/300mg XL), or mirtazapine. Exception: not required for members with agitation associated with dementia due to Alzheimer's disease.

    • Record trial details or documented intolerance/contraindication to one of the specified agents before approving Auvelity.
    Step Therapy

    Trintellix step requirement

    Trintellix follows the same step therapy requirement as Auvelity: require trial or documented inability to use the listed generic SSRIs, SNRIs, specified bupropion products, or mirtazapine.

    • Apply the same documentation of trial or intolerance as required for Auvelity when requesting Trintellix.
    Documentation Required

    Antidepressant trial or intolerance documentation

    Document that the member tried or cannot use the listed generic antidepressants (SSRIs, SNRIs, specified bupropion formulations, or mirtazapine) or provide evidence of contraindication or intolerance as applicable.

    • Include medication names, dates of trial, reason for discontinuation (e.g., intolerance, adverse effect, contraindication) in the prior‑auth request.
    Documentation Required

    Seizure therapy history

    For levetiracetam-containing products (including Spritam), provide evidence of prior therapy with levetiracetam and one of the following: lamotrigine, carbamazepine, topiramate, divalproex, or phenytoin to support automatic approval.

    • Document prior medications and timeframes showing levetiracetam plus one listed antiepileptic were used.
    Denial Risk

    Prerequisite therapy required

    Requests may be denied if the member has not tried or cannot use the specified prerequisite therapies when required (for example, the generic SSRI/SNRI, bupropion formulations, or mirtazapine for Auvelity/Trintellix).

    • Ensure required prior‑therapy trials or documented contraindications/intolerances are included to avoid denial.
    Prior Authorization

    Prior fenofibrate treatment required

    Fenofibrate micronized requires prior treatment with one strength of a generic fenofibrate tablet (145 mg, 160 mg, 48 mg, or 54 mg) AND one strength of a generic fenofibrate micronized capsule (200 mg, 134 mg, or 67 mg) for automatic approval.

    • Provide records showing prior use of both a generic fenofibrate tablet strength and a micronized capsule strength.

    Initial Therapy — Drug-specific Step Requirements

    Oral anticoagulant initial therapy

    Eliquis/Eliquis Sprinkle/Xarelto/rivaroxaban initial rules

    Anticoagulant prior therapy or age: Member has prior treatment, contraindication, or intolerance with the tablet product (Eliquis/apixaban or Xarelto/rivaroxaban) OR the member is 17 years of age or younger.age <= 17 qualifies

    automatic approval when met

    Step Therapy Tables — Required Prior Agents

    DrugStep therapy requirement
    Auvelity
    Trial or documented inability to use a generic SSRI (citalopram, fluoxetine, paroxetine, or sertraline), a generic SNRI (venlafaxine or duloxetine), a generic bupropion product (75/100 mg IR, 100/150/200 mg SR, or 150/300 mg XL), or mirtazapine; exception: not required for members with agitation associated with dementia due to Alzheimer's disease.
    DrugStep therapy requirement
    Trintellix
    Trial or documented inability to use a generic SSRI (citalopram, fluoxetine, paroxetine, or sertraline), a generic SNRI (venlafaxine or duloxetine), a generic bupropion product (75/100 mg IR, 100/150/200 mg SR, or 150/300 mg XL), or mirtazapine.
    DrugStep therapy requirement
    Fenofibrate micronized
    Member must have had previous treatment with one strength of generic fenofibrate tablet (145 mg, 160 mg, 48 mg, or 54 mg) AND one strength of generic fenofibrate micronized capsule (200 mg, 134 mg, or 67 mg).
    DrugStep therapy requirement
    Levetiracetam (including Spritam)
    Member must have had prior therapy with levetiracetam AND one of the following: lamotrigine, carbamazepine, topiramate, divalproex, or phenytoin.

    Background and Definitions

    This policy lists step therapy and automatic-approval rules that link specified specialty or brand drugs to required prior therapies, documented contraindications or intolerances, or defined exceptions to guide prior authorization decisions. For example, Auvelity is eligible for automatic approval when the member has tried or cannot use a generic SSRI (citalopram, fluoxetine, paroxetine, sertraline), a generic SNRI (venlafaxine, duloxetine), a specified generic bupropion formulation (75/100 mg IR; 100/150/200 mg SR; 150/300 mg XL), or mirtazapine — except where a stated exception (agitation associated with Alzheimer’s dementia) applies.

    Automatic approval definition
    DefinitionApproval granted when the member has documented prior treatment, contraindication, intolerance, or meets specified exceptions as listed for each drug.
    When it appliesAutomatic approval is given when the member has tried or cannot use specified prerequisite therapies (for example, generic SSRI, SNRI, specified bupropion formulations, or mirtazapine).
    Documentation requiredProvider must document trial of, or documented inability to use, the listed prior therapies or a contraindication/intolerance.
    ScopeThis definition applies across listed drug entries that specify automatic approval when prerequisite treatment, contraindication, intolerance, or age-based exceptions are met.
    Policy Summary
    PayerIntegrated Home Care Services
    PolicyStep Therapy Criteria for Select Pharmacy Drugs (AUVELITY and others)
    Policy CodePolicy N/A
    Change TypeRoutine review — no material changes
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionDocument prior trial or inability to use the listed generic therapies (e.g., SSRIs, SNRIs, bupropion, mirtazapine) to support automatic approval for Auvelity or Trintellix.
    SourceLink
    On This Page
    Coverage Criteria — Step Therapy and Prior Treatment RulesProvider Actions, Documentation & Automatic Approval ConditionsInitial Therapy — Drug-specific Step RequirementsStep Therapy Tables — Required Prior AgentsBackground and Definitions